Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
News|Articles|July 15, 2013
- Pharmaceutical Technology-07-15-2013
- Volume 2013 eBook
- Issue 1
Characterization with Atomic Force Microscopy, Topographic, and 3D Raman
The authors describe how a combination of imaging techniques can be used to provide topographic and chemical information to characterize a sample.
Advertisement
Highly specified drug-delivery systems require specific quality evaluation during the development stage. The authors describe how a combination of imaging techniques can be used to provide topographic and chemical information to characterize a sample three-dimensionally, underneath, and at the surface in a nondestructive manner.
Articles in this issue
over 13 years ago
Identification and Quantification of Trace-Level Protein Impuritiesover 13 years ago
Ultra-High-Speed Analysis of Ibuprofen Using HPLCAdvertisement
Related to this article
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
Onshoring pharmaceutical manufacturing can be made more practical by collaborating with CDMOs that have gray space, supported by strong relationships with used equipment dealers and OEMs.
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
4
ADCs, Degraders, Agonists: 4 Deals CMC Teams Should Track
5